Welcome to the Illinois Medical Oncology Society

IMOS is dedicated to ensuring you stay informed during the COVID-19 crisis. Click above to find all of the latest resources from ASCO, ASH, COA, HOSS, and important Industry News related to the crisis.

Illinois Department of Public Health COVID-19 Resources, Click here for more.


Formed on July 29, 1989, the Illinois Medical Oncology Society (IMOS) represents the common interests of a majority of the oncologists treating cancer in Illinois. As the oncology society in Illinois, we strive to provide our members with innovative resources to help them stay ahead of the shifting healthcare landscape and challenges that directly impact the high-quality care their patients deserve.

The Illinois Medical Oncology Society now offers FREE  memberships to oncologists and allied oncology professionals.

Find out more about membership

The IMOS board would also like to hear from you (all levels and types of members and potential members) about things you’d like to see for 2022 and how we can best serve your needs.

We are a State Affiliate of the American Society of Clinical Oncology.

Our Mission

We strive to promote the highest professional standards of oncology in the State of Illinois.  We create educational experiences for our members to exchange information to increase the quality of care for our patients. We act as a patient advocate to assure that patients have access to the best available care; and support and encourage clinical research against cancer.

Find out more

 


IMPORTANT INFORMATION FOR ALL PROVIDERS
FROM THE AMERICAN MEDICAL ASSOCIATION

As of January 1, 2021, there were significant changes to the office and outpatient Evaluation and Management (E&M) services (CPT ® codes 99202-99215) for both new and established patients.

Find out more

PHYSICIAN JOB OPPORTUNITY - OSF Bobette Steely Hegeler Cancer Care Center in Danville, Illinois, seeking Oncologist/Hematologist.  Click HERE for more information and HERE to go directly to the application site.


Drug Safety Communication

The U.S. Food and Drug Administration (FDA) is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib) approved to treat two specific types of lymphomas, which are cancers that affect the body’s immune system. We determined that initial findings from a clinical trial evaluating Ukoniq to treat a related type of cancer found a possible increased risk of death in patients taking the medicine. Because of the seriousness of this safety concern and the similarities between the two types of cancer for which this drug is approved and the type of cancer that was studied in the clinical trial, we are alerting patients and health care professionals that we are re-evaluating this risk against the benefits of Ukoniq for its approved uses.

For more information, read the complete Drug Safety Communication.


CDER Drug Safety Priorities 2021 Report

The CDER Drug Safety Priorities 2021 report details CDER's work to manage drug safety issues through modernized safety surveillance methods and innovative responses to safety concerns. The report highlights key safety-related milestones and accomplishments of 2021, as well as the many ways in which CDER has continued to be involved in promoting and protecting public health during the SARS-CoV-2 coronavirus (COVID-19) pandemic. The report focuses on the programs and initiatives at the core of CDER's drug safety operations, including the FDA Adverse Event Reporting Systems, the Sentinel System, and the Safe Use Initiative. It also features ongoing activities to address the national opioid crisis and misuse and abuse of other substances, work in addressing unexpected -- and potentially cancer-causing -- impurities in medicines, use of a broad range of communications tools and technologies such as Drug Safety Communications to transparently communicate drug safety to the public, and research being conducted CDER-wide to better understand drug safety risks.

Online Resources

Academy Managed Care Pharmacists Webinar on the use of BeiGene’s FDA-Approved BTK Inhibitor for the treatment of Mantle Cell Lymphoma, sponsored by BeiGene. Click HERE for more information and to view the webinar.

IMOS is happy to have partnered with NCODA to present their most recent webinars. You can watch all five parts of the COVID-19 series and a special ASCO/NCODA webinar on Patient-Centered Standards for Medically Integrated Dispensing by clicking HERE.  


Why the Patient Voice Matters

Recently Bristol Myers Squibb’s U.S. Policy & Government Affairs team held an interactive discussion with state & federal policymakers on the importance of the patient voice in the legislative process.

The forum provided an opportunity for attendees to hear directly from current legislators as they provided their insights on effective advocacy strategies and engagement with elected officials. During the discussion, the panelists shared what they seek to learn when meeting with advocates, first-hand examples of advocacy campaigns that have impacted their decision-making, tips for virtual advocacy engagement, and advice for any advocate looking to get involved in the legislative process.

To listen to this recent webinar please use the following link:

Why the Patient Voice Matters: Legislator Roundtable Forum (virtualpolicyforum.com)


Vaccines.gov Website and Text Service

Vaccines.gov, which compliments state and pharmacy websites connecting Americans to vaccines, is available in English and Spanish to help people find a vaccine location. A text message service is also available by texting your ZIP code to 438829 (GETVAX) and 822862 (VACUNA) to find three locations nearby that have vaccines available. The National COVID-19 Vaccination Assistance Hotline is also available to help those who prefer to get information by phone on where to get a vaccine. Call 1-800-232-0233 to find a location near you.

STATE CANCER FACT SHEETS AVAILABLE

The 2021 State Cancer Fact Sheets for all fifty states plus the District of Columbia and Puerto Rico are now available on myAffiliates and ASCO’s webpage. The fact sheets contain key cancer and health care data from each state and highlight the impact of NIH funding in your state. These fact sheets are useful background materials for meetings with legislative staff and can aid your advocacy efforts. Contact [email protected] for help with coordinating your advocacy activities.